Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07215559 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment closed, study ongoing Eligibility criteria expanded, about 28 words · Site details revised at 42 of 42 sites Show 2 more changesShow less
    • Eligibility criteria expanded, about 28 words
    • Site details revised at 42 of 42 sites
  2. Site contacts updated at 1 of 42 sitesv17
  3. Site contacts updated at 1 of 42 sitesv16
  4. Site details revised at 3 of 42 sitesv15
  5. Site details revised at 4 of 42 sitesv14
  6. Site contacts updated at 1 of 42 sitesv13
  7. Trial sites expanded: 38 → 42 locationsv12
  8. Site contacts updated at 1 of 38 sitesv11
  9. Study sites revised (38)v10 See this version in full on ClinicalTrials.gov ↗
  10. Site details revised at 7 of 38 sitesv9
  11. Site details revised at 1 of 38 sitesv8
  12. Site details revised at 5 of 38 sitesv7
  13. Site details revised at 11 of 38 sitesv6
  14. Site details revised at 3 of 38 sitesv5
  15. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Nov 2025 to Oct 16, 2025 · Site details revised at 38 of 38 sitesv4 Show 2 more changesShow less
    • Start date changed from estimate of Nov 2025 to Oct 16, 2025
    • Site details revised at 38 of 38 sites
  16. Study sites revised (38)v3 See this version in full on ClinicalTrials.gov ↗
  17. Site contacts updated at 1 of 38 sitesv2
  18. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
359 trials monitored
See 15 trials at risk
Diabetes
4,286 trials monitored
See 187 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
Type 2 Diabetes
2,100 trials monitored
See 102 trials at risk
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.
Trial Details
NCT Number NCT07215559
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight, Diabetes Mellitus, Type 2
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov